Urinary NO3- excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-name in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 1, 1996, Pages 11-15

  Böger, Rainer H ^a   Bode Böger, Stefanie M ^a   Gerecke, Uwe ^a   Gutzki, Frank M ^a   Tsikas, Dimitrios ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclic GMP; Endothelium derived relaxing factor; Gas chromatography; L arginine; N nitro L arginine

Indexed keywords

ARGININE; CREATININE; CYCLIC GMP; ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE;

ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG EFFECT; METABOLISM; MICTURITION; RAT; TIME; URINE; WISTAR RAT;

ANIMALS; ARGININE; CREATININE; CYCLIC GMP; ENZYME INHIBITORS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITES; RATS; RATS, WISTAR; TIME FACTORS; URINATION;

EID: 0029692620     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb03055.x     Document Type: Article

References (34)

1. Leaf CD, Wishnok JS, Tannenbaum SR. L-Arginine is a precursor for nitrate biosynthesis in humans. Biochem. Biophys. Res. Commun. 1989; 163: 1032-7.
2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
3. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl Acad. Sci. USA 1989; 86: 3375-8.
4. Moncada S, Radomski MW, Palmer RMJ. Endothelium-derived relaxing factor: Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem. Pharmacol. 1988; 37: 2495-501.
5. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest. 1986; 78: 1-5.
6. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 1987; 92: 639-46.
7. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 535-60.
8. Tolins JP, Palmer RMJ, Moncada S, Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am. J. Physiol. 1990; 27: H655-62.
9. 2 as internal standard. Biol. Mass Spectrom. 1992; 21: 97-102.
10. - excretion in the urine as an indicator of endothelium-derived relaxing factor during elevation of blood pressure. Clin. Sci. 1992; 82: 631-4.
11. Böger RH, Bode-Böger SM, Gerecke U, Frölich JC. Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats: Correlation with vascular reactivity. Cardiovasc. Res. 1994; 28: 494-9.
12. G-nitro-L-arginine methyl ester in conscious, unrestrained rats. J. Cardiovasc. Pharmacol. 1991; 17(Suppl. 3): S173-81.
13. G-nitro-L-arginine induces sustained hypertension in normotensive Wistar-Kyoto rats. Clin. Exp. Pharmacol. Physiol. 1992; 19: 583-6.
14. Johnson RA, Freeman RH. Pressure natriuresis in rats during blockade of the L-arginine/nitric oxide pathway. Hypertension 1992; 19: 333-8.
15. Radermacher J, Klanke B, Schurek H-J, Stolte HF, Frölich JC. Importance of EDRF/NO for glomerular and tubular function: Studies in the isolated perfused rat kidney. Kidney Int. 1992; 41: 1549-59.
16. Lahera V, Navarro J, Biondi ML, Ruilope LM, Romero JC. Exogenous cGMP prevents decrease in diuresis and natriuresis induced by inhibition of NO synthesis. Am. J. Physiol. 1993; 264: F334-47.
17. Kuhn M, Otten A, Frölich JC, Förstermann U. Endothelial cGMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. J. Pharm. Exp. Ther. 1991; 356: 677-82.
18. 15N]-nitrate in biological fluids. Anal. Biochem. 1982; 126: 131-8.
19. Wennmalm A, Benthin G, Petersson A-S. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br. J. Pharmacol. 1992; 106: 507-8.
20. Green LC, Ruiz de Luzuriaga K, Wagner DA et al. Nitrate biosynthesis in man. Proc. Natl Acad. Sci. USA 1981; 78: 7764-8.
21. Green LC, Tannenbaum SR, Goldman P. Nitrate synthesis in the germfree and conventional rat. Science 1981; 212: 56-8.
22. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis and endogenous roles of nitric oxide. Pharmacol. Rev. 1991; 43: 109-42.
23. Schmidt HHHW, Nau H, Wittfoht W et al. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur. J. Pharmacol. 1988; 154: 213-16.
24. Wennmalm A, Benthin G, Edlund A et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ. Res. 1993; 73: 1121-7.
25. Pfeilschifter J, Vosbeck K. Transforming growth factor β2 inhibits interleukin 1β- and tumor-necrosis-factor α-induction of nitric oxide synthase in rat mesangial cells. Biochem. Biophys. Res. Comm. 1991; 175: 372-9.
26. ω-nitro-L-arginine: A potent inhibitor of the L-arginine-dependent soluble guanylate cyclase activation pathway in LLC-PK1 cells. Can. J. Physiol. Pharmacol. 1990; 68: 749-51.
27. Welch WJ, Wilcox CS, Aisaka K et al. Nitric oxide synthesis from L-arginine modulates renal vascular resistance in isolated perfused and intact rat kidneys. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 3): S165-8.
28. Salazar FJ, Pinilla JM, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension 1992; 20: 113-17.
29. Zambetis M, Dusting GJ, Rajanayagam S, Woodman OL. Mechanism of the hypertension produced by inhibition of nitric oxide biosynthesis in rats. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 3): S191-7.
30. G-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br. J. Pharmacol. 1990; 101: 10-12.
31. Ward JE, Angus JA. Acute and chronic inhibition of nitric oxide synthase in conscious rabbits: Role of nitric oxide in the control of vascular tone. J. Cardiovasc. Pharmacol. 1993; 21: 804-14.
32. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 1992; 90: 647-52.
33. Lahera V, Salom MG, Miranda F, Moncada S, Romero JC. Effects of N-nitro-L-arginine methylester on renal function and blood pressure. Am. J. Physiol. 1991; 261: F1033-7.
34. Smoyer WE, Brouhard BH, Rassin DK, LaGrone L. Enhanced GFR response to oral versus intravenous L-arginine administration in normal adults. J. Lab. Clin. Med. 1991; 118: 166-75.